ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1735

Role of Repeated Renal Biopsy in ANCA Vasculitis

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Baaziz, Maroua, Hopital Europeen Georges Pompidou, Paris, Île-de-France, France
  • Thervet, Eric, Hopital Europeen Georges Pompidou, Paris, Île-de-France, France
  • Karras, Alexandre, Hopital Europeen Georges Pompidou, Paris, Île-de-France, France

Pauci-immune necrotizing crescentic glomerulonephritis is a severe renal complication of AAV. Despite immunosuppressive therapy, relapses are frequent during the course of the disease.
Kidney biopsy is routinely used to diagnose AAV at initial presentation. Although the activity of renal AAV is not easily evaluated by plasma or urine biomarkers, kidney biopsy is rarely performed when relapse is suspected.
We herein analyze the clinical, laboratory and renal pathology data from patients who underwent repeated kidney biopsies during the course of AAV.


We retrospectively reviewed data from 37 patients who underwent at least 2 kidney biopsies in our centre, between 2002 and 2018. The first renal biopsy (B1) was constantly performed at diagnosis. A follow-up biopsy (B2) was performed for purpose, either for suspicion of refractory disease or confirmation of renal relapse.
Modifications of renal pathology between B1 and B2 were studied, by comparing presence of active and chronic lesions.


The median delay between B1 and B2 was 3,3 [0,9-5,8] years. B2 was done for suspicion of refractory disease (n=8) or of renal relapse (n=29). Causes of B2 were : persistence or reappearance of haematuria in 78% of cases, increase of creatinine in 43%, increase of ANCA titer in 67%.
Systemic AAV activity was more important at B1 vs B2 (median BVAS 18 vs 9), as well as renal dysfunction (median sCreat 200 vs 156 μmol/l).
Active glomerulonephritis was constantly found at B1 but was present in only 35% of B2. Presence of cellular crescents decreased from 71,4 to 29,7% (p = 0,002), whereas fibrinoid necrosis decreased from 80,6 to 35,1% (p = 0.0003).
Five factors were significantly associated with the presence of active lesions : presence of at least one extra-renal AAV manifestation (p = 0.0006), increase of ANCA titer (p = 0.0022), CRP>30mg/l (p = 0.001), absence of IF/TA (p=0,02) and high percentage of normal glomeruli (p=0,014) at B1. Interestingly, level of proteinuria and persistence of hematuria were not associated with histological activity at B2 (p =0,64 and 0,22 respectively).
In contrast, chronic lesions were more severe at B2 compared to B1 (p <0,0001 and 0,014 respectively).


Despite several clinical and laboratory signs suggesting active renal AAV, B2 revealed no relapse in 2/3 of cases, allowing avoidance of a new immunosuppressive induction treatment.